Butenafine 1% versus terbinafine 1% in cream for the treatment of tinea pedis. A placebo-controlled, double-blind, comparative study

Clinical Drug Investigation

Volumn 19, Issue 6, 2000, Pages 393-397

  Syed, Tanweer A ^a   Hadi, Suhail M ^d   Qureshi, Zulfiqar A ^b   Ali, Shahida M ^a   Ahmad, Seyed Ali ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF THE PUNJAB   (Pakistan)

^c PACIFIC UNION COLLEGE   (United States)

^d Box 0989 ^*

Author keywords

[No Author keywords available]

Indexed keywords

BUTENAFINE; POTASSIUM HYDROXIDE; TERBINAFINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FUNGUS CULTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TINEA PEDIS;

EID: 0034086620     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019060-00001     Document Type: Article

References (15)

1. 1. Leyden JL. Tinea pedis: pathophysiology and treatment. J Am Acad Dermatol 1994; 31 (3 Pt 2): S31-S33
2. 2. Odom RB. Pathophysiology of dermatophyte infections. J Am Acad Dermatol 1993; 28 Suppl.: S2-S7
3. 3. Raboohee N, Aboobaker J, Peer AK. Tinea pedis et unguium in the Muslim community of Durban, South Africa. Int J Dermatol 1998; 37: 759-65
4. 4. Petranyi G, Ryder NS, Stütz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239-41
5. 5. Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23: 782-5
6. 6. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol 1997; 36 (2 Pt 1) S3-S8
7. 7. Tschen E, Elewski B, Gorsulowsky DC, et al. Treatment of interdigital tina pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997; 36 (2 Pt 1); S9-S14
8. 8. Stütz A. Synthesis and structure-activity correlations within allylamine Antimycotics. Ann N Y Acad Sci 1988; 554:46-62
9. 9. Arika T, Yokoo M, Yamaguchi H. Topical treatment with butenafine significantly lowers relapse rate in an interdigital tinea pedis model in guinea pigs. Antimicrob Agents Chemother 1992; 36: 2523-5
10. 10. Reyes BA, Beutner KR, Cullin SI, et al. Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. Int J Dermatol 1997; 37: 450-3
11. 11. Nahm WK, Orengo I, Rosen T. The antifungal agent butenafine manifests anti-inflammatory activity in vivo. J Am Acad Dermatol 1999; 41: 203-6
12. 12. Tsuyuki S, Ito M, Unno T, et al. Clinical usefulness of butenafine chloride on tinea pedis: comparison study with clotrimazole. Acta Dermatol 1990; 85: 299-306
13. 13. Evans EG, Dodman B, Williamson DM, et al. Comparison of terbinafine and clotrimazole in the treatment of tinea pedis. BMJ 1993; 307: 645-7
14. 14. Bergstresser PR, Elewski BE, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with I-and 4 week treatment regimens. J Am Acad Dermatol 1993; 28: 648-51
15. 15. Wahid Z, Butt J, Nishtar R. Multicenler double-blind study of efficacy and safety of terbinafine 1% cream compared with bifonazole 1% cream in patients with tinea pedis moccasin type. J Dermatol Treatment 1997; 8: 225-7